logo
Oura, Maven Clinic team up to bring biometric data into clinical care

Oura, Maven Clinic team up to bring biometric data into clinical care

CNBC18-06-2025
Women's and family health platform Maven Clinic is partnering with smart ring maker Oura, a step forward in the integration of the increasing amount of data being collected by wearable devices and clinical care.
As part of the partnership, eligible Maven members will be able to sync the data that their Oura Ring collects with the Maven platform, allowing members of the Maven care team to comb over the Oura-collected data like sleep, stress and activity to provide enhanced health guidance.
Maven Clinic, a three-time CNBC Disruptor 50 company, is the largest virtual clinic for women's and family health with more than 2,000 employers and health plans using its platform. The company, which raised a $125 million funding round valuing it at $1.7 billion in October 2024, offers programs that range from fertility and family building to maternity and newborn care to menopause and midlife health.
Kate Ryder, CEO and founder of Maven Clinic, said that we're in a "reinvigorated era of consumer health," a period that is being defined by the amount of data being collected via wearables and the desire of people to use those diagnostics to seek treatment and advice.
Ryder said that a recent survey of Maven Clinic members found that nearly three out of four members are tracking their health regularly with some sort of device, and consumers are asking, "How do I take my health into my own hands with all these tools and areas of wellness at my fingertips to try to live a healthier life?"
That shift prompted Maven's new partnership with Oura, also a three-time Disruptor 50 company, which was ranked No. 23 on the 2025 CNBC Disruptor 50 list and has been on its own path of wellness and preventive health via its eponymous Ring in recent years.
While Oura's initial focus centered on tracking sleep and recovery metrics, its scope has widened significantly in recent years to broader healthcare and personal health issues. As Oura CEO Tom Hale said in a recent CNBC interview, "the vision for the future of Oura has to do with the doctor in your pocket."
That includes a wide variety of metrics, features and health indicators tracked by the Oura Ring and parsed by the company's AI and analytics to offer wearers' health insights, including a variety of female-focused features around menstrual, period and pregnancy cycles.
"One of our key theses is that women have been overlooked in science, and in health understudied and overlooked, but we believe that they expect the same level of personalization, transparency and immediacy from their healthcare," said Oura chief commercial officer Dorothy Kilroy. "This is what they want, and traditional healthcare hasn't really kept up with that for women and their families."
Kilroy said that the partnership between the two companies aims to deliver that, offering "smart, connected personalized care that'll fit into their lives and not the other way around, which is kind of what the old healthcare systems have provided."
The ultimate goal is to improve health outcomes through the utilization of the data collected by the Oura Ring, allowing for more personalized recommendations, the ability to catch issues sooner and be more proactive, and layering in expert medical care at critical points.
"Tracking is the first step, but really it's not just about surfacing health data," Ryder said, noting that Maven Clinic is the first virtual care platform to turn Oura's health signals into expert care. "We really want to act on it to actually drive better outcomes."
One example of how the data could be utilized would be in the case of a pregnant Maven member diagnosed with gestational diabetes. That person could work with a Maven nutritionist or support coach to help regulate their glucose levels, while using Oura's physical activity tracking and meals and glucose features to monitor their progress.
Oura is increasingly working with a variety of partners in the healthcare sector to use the biometric data collected by its Rings, Kilroy said, allowing it to be "paired with clinical care and creating that kind of seamless experience where the members can both understand what's going on in their body but they can actually use that to get expert care all in one place."
Ryder said that she sees the convergence of this sort of biometric tracking and the clinical side as leading towards much more effective preventative care, leading to "much better outcomes," especially among high-risk patients where this sort of reporting and engagement can result in significant improvements in health.
Maven Clinic will start to integrate the Oura data into its platform starting later this summer, with a goal of having it reach all members who want to opt in by the winter. Maven members will also receive exclusive pricing on the purchase of an Oura Ring.
"We have to shift our healthcare system into prevention and invest more in wellness and wellbeing," Ryder said. "There's a lot of exciting stuff that this partnership can do to take the step forward, be innovative and show the outcomes on the back end."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

3 Industrials Stocks with Warning Signs
3 Industrials Stocks with Warning Signs

Yahoo

time17 hours ago

  • Yahoo

3 Industrials Stocks with Warning Signs

Whether you see them or not, industrials businesses play a crucial part in our daily activities. They are also bound to benefit from a friendlier regulatory environment with the Trump administration, and this excitement has led to a six-month gain of 7.5% for the sector - higher than the S&P 500's 5.5% return. Although these companies have produced results lately, a cautious approach is imperative. When the cycle naturally turns, the losers can be left for dead while the winners consolidate and take more of the market. Keeping that in mind, here are three industrials stocks we're steering clear of. Ryder (R) Market Cap: $7.43 billion As one of the first companies to introduce the idea of leasing trucks, Ryder (NYSE:R) provides rental vehicles to businesses and delivers packages directly to homes or businesses. Why Is R Risky? Annual sales growth of 3% over the last two years lagged behind its industrials peers as its large revenue base made it difficult to generate incremental demand Earnings per share have dipped by 7.4% annually over the past two years, which is concerning because stock prices follow EPS over the long term Free cash flow margin dropped by 9.5 percentage points over the last five years, implying the company became more capital intensive as competition picked up Ryder's stock price of $182.11 implies a valuation ratio of 12.9x forward P/E. To fully understand why you should be careful with R, check out our full research report (it's free). Gorman-Rupp (GRC) Market Cap: $1.11 billion Powering fluid dynamics since 1934, Gorman-Rupp (NYSE:GRC) has evolved from its Ohio origins into a global manufacturer and seller of pumps and pump systems. Why Does GRC Worry Us? Muted 3.3% annual revenue growth over the last two years shows its demand lagged behind its industrials peers Demand will likely be soft over the next 12 months as Wall Street's estimates imply tepid growth of 3.7% Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 4.7 percentage points Gorman-Rupp is trading at $43.59 per share, or 18.9x forward P/E. If you're considering GRC for your portfolio, see our FREE research report to learn more. Proto Labs (PRLB) Market Cap: $1.14 billion Pioneering the concept of online quoting and manufacturing for custom prototypes and low-volume production parts, Proto Labs (NYSE:PRLB) offers injection molding, 3D printing, and sheet metal fabrication for manufacturers in various industries. Why Should You Sell PRLB? Annual revenue growth of 2.4% over the last two years was below our standards for the industrials sector Efficiency has decreased over the last five years as its operating margin fell by 7.6 percentage points Earnings per share have contracted by 9.3% annually over the last five years, a headwind for returns as stock prices often echo long-term EPS performance At $47.85 per share, Proto Labs trades at 32.3x forward P/E. Check out our free in-depth research report to learn more about why PRLB doesn't pass our bar. High-Quality Stocks for All Market Conditions Donald Trump's April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities. The smart money is already positioning for the next leg up. Don't miss out on the recovery - check out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

Evernow Partners with ŌURA to Combine Symptom Tracking with Personalized Menopause Care
Evernow Partners with ŌURA to Combine Symptom Tracking with Personalized Menopause Care

Yahoo

timea day ago

  • Yahoo

Evernow Partners with ŌURA to Combine Symptom Tracking with Personalized Menopause Care

SAN FRANCISCO, Aug. 14, 2025 /PRNewswire/ -- Evernow, the leading telehealth platform for menopause care, is proud to announce a partnership with ŌURA, maker of the world's leading smart ring. As part of the launch of Oura's first-ever menopause feature, Perimenopause Check-In, Evernow will serve as a care partner to transform insight into action. Perimenopause is one of the most underrecognized phases in women's health, often lasting years and affecting everything from mood to sleep to cognitive clarity. Despite its widespread impact, many women struggle to get meaningful answers or support. By integrating real-time biometric data with access to expert care, this collaboration offers a new, proactive model for managing early hormonal changes. Oura members who complete the Perimenopause Check-In can now seamlessly access Evernow's clinician-led care, with the option to upload personalized Oura reports (including Sleep, Cycle, and Perimenopause data) directly before their visit. Evernow clinicians will use this data to inform and personalize treatment plans, connecting symptom awareness to timely, evidence-based care. "Millions of women are experiencing symptoms related to perimenopause, but haven't had the language or tools to act," said Alicia Jackson, CEO of Evernow. "This partnership helps them do both: understand what's happening in their bodies and connect with specially trained clinicians who can create tailored treatment plans, prescribe medication when appropriate, and offer guidance on managing symptoms day-to-day." Through the partnership with Evernow, Oura members can access: Video visits with menopause-trained clinicians in under 48 hours Insurance-covered menopause care across all 50 states Unlimited messaging with your provider Personalized treatment plans informed by Oura biometric reports Easy, convenient prescriptions with automated refills Learn more at Together, Evernow and Oura are making it easier for women to go from tracking symptoms to getting real care, bringing clarity, support, and faster access to treatment during one of the most overlooked stages of women's health. Contact:press@ View original content: SOURCE Evernow Sign in to access your portfolio

NASA has sparked a race to develop the data pipeline to Mars
NASA has sparked a race to develop the data pipeline to Mars

Yahoo

time2 days ago

  • Yahoo

NASA has sparked a race to develop the data pipeline to Mars

For decades, NASA built and flew its own relay orbiters and spacecraft to ferry valuable data back to Earth. Now, the agency is shifting to buying connectivity as a service, much like it does for launch and astronaut transport. That pivot has sparked a race, with major contenders pitching ways to keep Mars missions online. What's at stake isn't a single contract: it's the data pipe to Mars. This new approach, which will mix NASA assets and commercial infrastructure, would gradually replace the patchwork relay network the agency relies on today. Generally, that works by orbiters like Mars Reconnaissance Orbiter and MAVEN that pickup data from rovers and landers, and transmit it to the Deep Space Network's (DSN) giant antennas on Earth. NASA's relay spacecraft are still healthy, but they were never meant to be a permanent backbone. The agency's latest senior review on planetary missions calls out MAVEN's critical role as a relay and provides steps to keep it available into the early 2030s. But eventually, this hardware will decay. At the same time, NASA's Space Communications and Navigation (SCaN) program, which manages the DSN, is looking for solutions to augment these aging assets. The aim, according to an RFP released in July and due today, is to create an interoperable marketplace where NASA can be one of many customers instead of the owner-operator. The current request is specifically for capability studies, not immediate hardware buys. The ask is two-fold: a 'lunar trunkline' between the Moon and Earth, and end-to-end Mars communications that move data from assets on the surface, through Mars orbit, and to operations centers on Earth. It's a formidable challenge. Any architecture must contend with the vast distance between Earth and the Moon and Mars, long latency, periodic solar interference and Earth visibility windows, and high requirements for fault-tolerant systems. That's why NASA is asking for plans, to gauge how industry might solve these puzzles, rather than immediately jumping to procurement. While TechCrunch can't confirm which companies are submitting concept proposals, a handful have already staked their place in the race. Blue Origin just unveiled a Mars Telecommunications Orbiter built on its Blue Ring platform, pitched as maneuverable, high-performance spacecraft to support NASA missions to Mars as soon as 2028. Rocket Lab has touted its own Mars telecom orbiter concept, which the company says is a core element of its proposed architecture for the Mars Sample Return campaign. In 2024, NASA's Mars Exploration Program separately funded 12 short commercial services studies, including a trio of studies for next-gen relay services, to SpaceX, Lockheed Martin, and Blue Origin. SpaceX's proposal to 'adapt Earth-orbit communication satellites for Mars' will likely be derived from its Starlink internet satellite constellation. The long-term goal is to transform the agency's planetary exploration agenda from pure-science missions to a permanent human presence on the moon and, eventually, Mars. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store